AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 172 min read$KMTS

Webster Brian Daniel sold $312K of KMTS

Webster Brian Daniel (See Remarks) sold 15,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $20.81 ($0.31M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Jun 17, 2026, 8:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale of 15,000 shares by an officer/director under a pre-arranged Rule 10b5-1 plan; no new company fundamentals are stated.

02

Market read

Traders may treat this as low-signal insider activity; without accompanying fundamental news, it is unlikely to drive a sustained repricing.

03

What to watch

The article doesn’t disclose whether other insiders sold/bought around the same window, nor does it provide context on total insider holdings beyond the post-transaction figure.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-17; sale dated 2026-06-15

Background

This is an SEC Form 4 insider transaction for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS), reported via EDGAR.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows officer/director Webster Brian Daniel sold 15,000 KMTS shares on 2026-06-15 for about $312K under a 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The disclosure is a routine Form 4 sale with stated 10b5-1 pre-arrangement; no new operational, financial, or regulatory catalyst is provided.

Market effects

Sector

Minimal—this is company-specific insider transaction disclosure with no sector-wide datapoint.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can still coincide with internal expectations of near-term volatility or liquidity needs, so traders may watch for follow-on selling or unusual volume.

Key entities

  • equity issuer
    KMTS

    Subject of the Form 4 insider sale disclosure.

  • insider
    Webster Brian Daniel

    Officer/director who sold 15,000 shares on 2026-06-15 under a 10b5-1 plan.

Read at source← All news

Related articles

JUL 16
$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

yahoo.com6 min
JUL 15
$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

yahoo.com4 min
JUL 15
$KMTSMed

Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.

yahoo.com7 min
JUL 14
$KMTSMedAI 8/10

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies (Nasdaq: KMTS) announced a five-year, non-dilutive term loan facility managed by Pharmakon Advisors. It includes $75M funded at closing (used to retire a $45M loan plus fees), $25M available through July 2027, $50M through June 2028 subject to $150M trailing revenue, and a $50M acquisition tranche. Interest is SOFR plus 5.5% with a 3.25% floor; Kestra reported $262M cash/investments as of Apr. 30, 2026.

manilatimes.net4 min